The firm behind patented technology enabling it to add fat-soluble bioactives from omega-3s to CoQ10 to shelf stable clear beverages announced it has obtained a Notice-of-Allowance for patent application number 20090317532 by the USPTO.
“With such new technologies, we felt compelled to create a new space within our industry that is specific toward what it is Virun does; this new space will help accelerate new branded products and support current brands with shelf stable and clearer EPA DHA Omega-3 compounds,” said Philip Bromley, CEO of Virun.
The company describes Nutra-Biosciences as a combination of nutraceutical ingredients with biotechnology to deliver healthy compounds that are safe. This will help support the development of food and beverage applications containing novel compounds such as EPA DHA omega-3, lycopene, and astaxanthin, it added.
Founded in 2003, the California-based biotech firm is best known for its drug delivery platform, which uses natural transferrin technology to deliver drugs with increased oral bioavailability.
In the food and beverage industry, however, it is best known for developing encapsulation technologies that allow for improved absorption of non-polar or fat-soluble bioactive ingredients such as omega-3a, CoQ10, vitamin D3 and resveratrol. The company introduced its shelf-stable water-soluble nano omega-3 in 2009.
Uniquely, the ingredients/excipients used to deliver these bioactives do not get into the blood, said the firm, which has attracted interest from a range of leading players in the food and beverage industry, notably Hormel Foods, which uses Virun’s technology in its FUXIONS range of ingredients, said the firm.